Spectrum Pharmaceutecals Inc (SPPI)

[antihama]

No Poziotimib data at SABCS 2016? At least that's the way it looks like right now. Saw yesterday that PUMA PR'd their abstracts that will be available at SABCS so I'm thinking yesterday was the day that SABCS allows companies tp PR this info but not 100% sure since the only info about abstract release on the SABCS website was that it's available to participants at the meeting and available to non participants in January. So was waiting till this morning to see if SPPI was releasing anything on Hanmi's P2 open label study in Recurrent Stage IV BC, to date nada. As a comparison, Neratinib pts two-year disease free survival (DFS) came in at 93.9% versus 91.6% for the placebo arm so hopefully it's because it's not fully matured.

Also, Puma, at SABCS, released interim data on a P2 study that they were running showing they still had significant AEs (diarrhea) in pts taking neratinib w loperamide, an anti-diarrhea medicine so now they're starting a new cohort that will be taking another med (budesonide) in order to try to stop significant AEs. If that doesn't work there is speculation that the FDA might not approve the drug.